MedTrace Logo

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

NCT04684394 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-10-31

Study results available
· View outcomes & findings →

Summary

This study is designed to investigate the safety and tolerability of GEM103 IVT injection + standard of care vs. sham + standard of care.

Conditions

  • Neovascular Age-related Macular Degeneration
  • Retinal Disease
  • Retinal Degeneration
  • Macular Degeneration

Interventions

BIOLOGICAL

GEM103

GEM103 500 mcg/50 mcL intravitreal injection

DRUG

Aflibercept

Aflibercept 2 mg/50 mcL (SOC) intravitreal injection Sham intravitreal injection

DRUG

Sham

Sham intravitreal injection

Sponsors & Collaborators

  • Gemini Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-29
Primary Completion
2022-01-10
Completion
2022-02-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04684394 on ClinicalTrials.gov